About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2026№5

Algorithm for prescribing hormonal contraception and menopausal hormone therapy in perimenopause

DOI
https://dx.doi.org/10.18565/aig.2026.13

Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, International Association of Obstetricians-­Gynecologists and Endocrinologists, National Association of Obstetricians-­Gynecologists and Reproductologists «Women’s Health», Interdisciplinary Association of Healthy Aging Specialists, Interdisciplinary Association of Reproductive Medicine Specialists «MARS», Society of Obstetricians and Gynecologists of St. Petersburg and the North­-Western Region, Interdisciplinary Association of Specialists in Anti­-Aging Medicine

For citation: Algorithm for prescribing hormonal contraception and menopausal hormone therapy in perimenopause.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (5): 205-216 (in Russian)
https://dx.doi.org/10.18565/aig.2026.13

Full text (in Russian)

References

  1. Bartz D., Tadikonda A., Manson J.E. Opportunity for improved menopausal hormone therapy prescribing. JAMA. 2026; 335(15): 1297-99. https://dx.doi.org/10.1001/jama.2026.1891
  2. Panay N., Ang S.B., Cheshire R., Goldstein S.R., Maki P., Nappi R.E. Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper. Climacteric. 2024; 27(5): 441-57. https://dx.doi.org/10.1080/13697137.2024.2394950
  3. Письмо Министерства здравоохранения Российской Федерации от 8 апреля 2024 г. № 17-6/И/2-6434 «О направлении методических рекомендаций по диспансеризации мужчин и женщин репродуктивного возраста с целью оценки репродуктивного здоровья». Доступно по: https://www.garant.ru/products/ipo/prime/doc/408788357 [Letter of the Ministry of Health of the Russian Federation dated April 8, 2024 No. 17-6/I/2-6434 "On the direction of methodological recommendations for the medical examination of men and women of reproductive age in order to assess their reproductive health". Available at: https://www.garant.ru/products/ipo/prime/doc/408788357 (in Russian)].
  4. Сухих Г.Т., Прилепская В.Н., ред. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5 издание, 2015». М.; 2023. 272 с. [Sukhikh G.T., Prilepskaya V.N., eds. National Medical Criteria for the Acceptability of Contraceptive Methods. Adapted from the WHO Medical Criteria for the Acceptability of Contraceptive Methods, 5th edition, 2015. Moscow; 2023. 272 p. (in Russian)].
  5. Panay N., Fenton A., Hamoda H., Hillard T., Islam R., Pedder H. et al. International Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause. Climacteric. 2025; 28(6): 634-56. https://dx.doi.org/10.1080/13697137.2025.2585487
  6. Greendale G.A., Huang M., Cauley J.A., Matthews K.A., Gold E.B., Sowers M. et al. Trabecular bone score declines during the menopause transition: the Study of Women’s Health Across the Nation (SWAN). J. Clin. Endocrinol. Metab. 2019; 105(5): 1872-82. https://dx.doi.org/10.1210/clinem/dgz056
  7. Islam R.M., Bond M., Ghalebeigi A., Wang Y., Walker-Bone K., Davis S.R. Prevalence and severity of symptoms across the menopause transition: cross-sectional findings from the Australian Women's Midlife Years (AMY) Study. Lancet Diabetes Endocrinol. 2025; 13(9): 765-76. https://dx.doi.org/10.1016/S2213-8587(25)00138-X
  8. Gold E.B., Crawford S.L., Avis N.E., Crandall C.J., Matthews K.A., Waetjen L.E. et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. Am. J. Epidemiol. 2013; 178: 70-83. https://dx.doi.org/10.1093/aje/kws421
  9. Herber-Gast G.C., Mishra G.D., van der Schouw Y.T., Brown W.J., Dobson A.J. Risk factors for night sweats and hot flushes in midlife: results from a prospective cohort study. Menopause. 2013; 20(9): 953-9. https://dx.doi.org/10.1097/GME.0b013e3182844a7c
  10. Freeman E.W., Sammel M.D., Sanders R.J. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014; 21(9): 924-32. https://dx.doi.org/10.1097/GME.0000000000000196
  11. Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6): 510-20. https://dx.doi.org/10.1080/13697137.2024.2423213
  12. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and the menopausal state in women. 2025 (in Russian)].
  13. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95. https://dx.doi.org/10.1097/gme.0b013e31824d8f40
  14. Verrilli L., Berga S.L. What every gynecologist should know about perimenopause. Clin. Obstet. Gynecol. 2020; 63(4): 720-34. https://dx.doi.org/10.1097/GRF.0000000000000578
  15. Davis S.R., Taylor S., Hemachandra C., Magraith K., Ebeling P.R., Jane F. et al. The 2023 Practitioner’s toolkit for managing menopause. Climacteric. 2023; 26(6): 517-36. https://dx.doi.org/10.1080/13697137.2023.2258783
  16. Prior J.C. Perimenopause: the complex endocrinology of the menopausal transition. Endocr. Rev. 1998; 19(4): 397-428. https://dx.doi.org/10.1210/edrv.19.4.0341
  17. Hall J.E. Endocrinology of the menopause. Endocrinol. Metab. Clin. N. Am. 2015; 44(3): 485-96. https://dx.doi.org/10.1016/j.ecl.2015.05.010
  18. Lumsden M.A., Dekkers O.M., Faubion S.S., Hirschberg A.L., Jayasena C.N., Lambrinoudaki I. et al. European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur. J. Endocrinol. 2025; 193(4): G49-81. https://dx.doi.org/10.1093/ejendo/lvaf206
  19. Santoro N., Lasley B., McConnell D., Allsworth J., Crawford S., Gold E.B. et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: the Study of Women's Health across the Nation (SWAN) daily hormone study. J. Clin. Endocrinol. Metab. 2004; 89(6): 2622-31. https://dx.doi.org/10.1210/jc.2003-031578
  20. Perry J.R.B., Murray A., Day F.R., Ong K.K. Molecular insights into the aetiology of female reproductive ageing. Nat. Rev. Endocrinol. 2015; 11(12): 725-34. https://dx.doi.org/10.1038/nrendo.2015.167
  21. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гиперплазия эндометрия. 2025. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometrial hyperplasia. 2025 (in Russian)].
  22. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Аномальные маточные кровотечения. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Abnormal uterine bleeding. 2024 (in Russian)].
  23. Santoro N., Brown J.R., Adel T., Skurnick J.H. Characterization of reproductive hormonal dynamics in the perimenopause. J. Clin. Endocrinol. Metab. 1996; 81(4): 1495-501. https://dx.doi.org/10.1210/jcem.81.4.8636357
  24. Gordon J.L., Girdler S.S., Meltzer-Brody S.E., Stika C.S., Thurston R.C., Clark C.T. et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am. J. Psychiatry. 2015; 172(3): 227-36. https://dx.doi.org/10.1176/appi.ajp.2014.14070918
  25. Conklin M., Santoro N. Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause. Ther. Adv. Reprod. Health. 2023; 17: 26334941231177611. https://dx.doi.org/10.1177/26334941231177611
  26. Young Moss S., Lee A., Simon J.A. Advances in pharmacotherapy for menopausal vasomotor symptoms. Drugs. 2025; 85(11): 1363-79. https://dx.doi.org/10.1007/s40265-025-02231-8
  27. Santoro N., Epperson C.N., Mathews S.B. Menopausal symptoms and their management. Endocrinol. Metab. Clin. North Am. 2015; 44(3): 497-515. https://dx.doi.org/10.1016/j.ecl.2015.05.001
  28. Davis S.R., Lambrinoudaki I., Lumsden M., Mishra G.D., Pal L., Rees M. et al. Menopause. Nat. Rev. Dis. Primers. 2015; 1: 15004. https://dx.doi.org/10.1038/nrdp.2015.4
  29. Coslov N., Richardson M.K., Woods N.F. "Not feeling like myself" in perimenopause - what does it mean? Observations from the Women Living Better survey. Menopause. 2024; 31(5): 390-8. https://dx.doi.org/10.1097/GME.0000000000002339
  30. Bremer E., Jallo N., Rodgers B., Kinser P., Dautovich N. Anxiety in menopause: a distinctly different syndrome? J. Nurse Pract. 2019; 15(5): 374-8. https://dx.doi.org/doi.org/10.1016/j.nurpra.2019.01.018
  31. Gordon J.L., Girdler S.S., Meltzer-Brody S.E., Stika C.S., Thurston R.C., Clark C.T. et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal. depression: a novel heuristic model. Am. J. Psychiatry. 2015; 172(3): 227-36. https://dx.doi.org/10.1176/appi.ajp.2014.14070918
  32. Zheng Y., Manson J.E., Yuan C., Liang M.H., Grodstein F., Stampfer M.J. et al. Associations of weight gain from early to middle adulthood with major health outcomes later in life. JAMA. 2017; 318(3): 255-69. https://dx.doi.org/10.1001/jama.2017.7092
  33. Greendale G.A., Sternfeld B., Huang M., Han W., Karvonen-Gutierrez C., Ruppert K. et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019; 4(5): e124865. https://dx.doi.org/10.1172/jci.insight.124865
  34. Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардио­логического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. Акушерство и гинекология. 2023; 11: 211-32. [Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I., Arutyunov G.P., Suchkov I.A. Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Russian Phlebological Association. Obstetrics and Gynecology. 2023; (11): 211-32 (in Russian)]. https://dx.doi.org/10.18565/aig.2021.267
  35. Объединенная позиция российских экспертов по вопросу кли­ни­ческого значения гиперандрогении у женщин в ранней пост­-мено­­паузе. Акушерство и гинекология. 2025; 5: 201-6. [Joint position of Russian experts on the clinical significance of hyperandrogenism in early postmenopausal women. Obstetrics and Gynecology. 2025; (5): 201-6 (in Russian)]. https://dx.doi.org/10.18565/aig.2025.118
  36. Ling J., Wang Y.H. Association between depressive mood and body image and menopausal symptoms and sexual function in perimenopausal women. World J. Clin. Cases. 2023; 11(32): 7761-9. https://dx.doi.org/10.12998/wjcc.v11.i32.7761
  37. Saleh S.A., Almadani N., Mahfouz R., Nofal H.A., El-Rafey D.S., Seleem D.A. Exploring the intersection of depression, anxiety, and sexual health in perimenopausal women. Int. J. Womens Health. 2024; 16: 1315-27. https://dx.doi.org/10.2147/IJWH.S464129
  38. Tiwari M., Acharya N., Mahakarkar M. Navigating the vaginal milieu during perimenopause: a narrative review of physiological changes and clinical implications. J. Pharm. Bioallied Sci. 2025; 17(Suppl 1): S92-5. https://dx.doi.org/10.4103/jpbs.jpbs_1493_24
  39. North American Menopause Society. Menopause practice. Clinician's guide. 6th ed.; 2025. Available at: https://menopause.org/professional-resources/menopause-practice-textbook Yureneva S., Komedina V., Kuznetsov S. COCs with estradiol valerate/dienogest vs 17β estradiol/nomegestrol acetate: effects on metabolism and body composition in menopausal transition women. Maturitas. 2023; 173: 76-7.
  40. Kim Y., Cho M.K., Chung Y.J., Hong S.H., Hwang K.R., Jeon G.H. et al.; Publication Committee on Clinical Guidelines of the Korean Society of Menopause. The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause. J. Menopausal Med. 2025; 31(2): 53-84. https://dx.doi.org/10.6118/jmm.25103
  41. Fruzzetti F., Trémollieres F., Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate /dienogest. Gynecol. Endocrinol. 2012; 28(5): 400-8. https://dx.doi.org/10.3109/09513590.2012.662547
  42. Macìas G., Merki-Feld G.S., Parke S., Mellinger U., Serrani M. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J. Obstet. Gynaecol. 2013; 33(6): 591-6. https://dx.doi.org/10.3109/01443615.2013.800851
  43. Общая характеристика лекарственного препарата Клайра® от 31.05.2023. Доступно по: https://www.rlsnet.ru/drugs/klaira-40216 [General characteristics of the drug Qlaira®, 31.05.2023. Available at: https://www.rlsnet.ru/drugs/klaira-40216(in Russian)].
  44. Paoletti A.M., Lello S., Di Carlo C., Orrù M., Malune M.E., Neri M. et al. Effect of estradiol valerate plus dienogest on body composition of healthy women in the menopausal transition: a prospective one-year evaluation. Gynecol. Endocrinol. 2016; 32(1): 61-4. https://dx.doi.org/10.3109/09513590.2015.1079175
  45. Davis S.R., Bitzer J., Giraldi A., Palacios S., Parke S., Serrani M. et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J. Sex. Med. 2013; 10(12): 3069-79. https://dx.doi.org/10.1111/jsm.12310
  46. Caruso S., Agnello C., Romano M., Cianci S., Lo Presti L., Malandrino C. et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J. Sex. Med. 2011; 8(10): 2841-50. https://dx.doi.org/10.1111/j.1743-6109.2011.02409.x
  47. Караченцев А.П., Мельниченко Г.А. Выбор оптимального гестагена для комбинированной заместительной гормонотерапии в пери- и постменопаузе. Проблемы эндокринологии. 2006; 52(2): 7-16. [Karachentsev A.N., Melnichenko G.A. Choice of optimal gestagen for combined hormonal replacement therapy in the peri- and postmenopause. Problems of Endocrinology. 2006; 52(2): 7-16 (in Russian)]. https://dx.doi.org/10.14341/probl20065227-16
  48. Общая характеристика лекарственного препарата Евра® от 22.08.2025. Доступно по: https://www.vidal.ru/drugs/evra__6659?ysclid=moo86xvxdz170506629 [General characteristics of the drug Evra®, 22.08.2025. Available at: https://www.vidal.ru/drugs/evra__6659?ysclid=moo86xvxdz170506629 (in Russian)].
  49. Общая характеристика лекарственного препарата Мирена® от 03.02.2026. Доступно по: https://www.vidal.ru/drugs/mirena__440?ysclid=moo8okzi4u749067901 [General characteristics of the drug Mirena®, 03.02.2026. Available at: https://www.vidal.ru/drugs/mirena__440?ysclid=moo8okzi4u749067901 (in Russian)].
  50. Общая характеристика лекарственного препарата Кайлина® ЛНГ от 15.04.2024. Доступно по: https://www.vidal.ru/drugs/kailina-lng?ysclid=moo8u35u2u368165087 [General characteristics of the drug Kyleena® LNG, 15.04.2024. Available at: https://www.vidal.ru/drugs/kailina-lng?ysclid=moo8u35u2u368165087 (in Russian)].
  51. Общая характеристика лекарственного препарата Фемостон® 1 от 16.09.2025. Доступно на: https://www.vidal.ru/drugs/femoston_1_10__1276?ysclid=moo8yj965j547226292 [General characteristics of the drug Femoston® 1, 16.09.2025. Available at: https://www.vidal.ru/drugs/femoston_1_10__1276?ysclid=moo8yj965j547226292 (in Russian)].
  52. Общая характеристика лекарственного препарата Фемостон® 2 от 18.09.2025. Доступно по: https://www.vidal.ru/drugs/femoston_2_10__1275?ysclid=moo92s7tyw957576857 [General characteristics of the drug Femoston® 2, 18.09.2025. Available at: https://www.vidal.ru/drugs/femoston_2_10__1275?ysclid=moo92s7tyw957576857 (in Russian)].
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.